10th annual Immuno-Oncology Summit
Over the past 10 years, CHI’s Immuno-Oncology Summit has become the leading annual meeting focusing on the latest applied research, providing comprehensive and in-depth coverage…
Read more
IWHM6 | Biocytogen to Present 12 Posters on Innovative Mouse and Rat Models
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) will attend the 6th International Workshop on Humanized Mice (IWHM6) held in Kyoto University, Japan, from October…
Read more
Research Impact: B-NDG Mice Used to Identify Lipid Transport Mechanism Driving T Cell Leukemogenesis
By John Charpentier, Ph.D. September 29, 2022 A recent study featuring Biocytogen mice identifies a non-vesicular lipid transport mechanism required for T cell leukemogenesis. Wenbing…
Read more
Biocytogen to Present at BioJapan2022, Introducing Innovative R&D Platforms, Bispecific ADC Programs and Pipeline Progress
Biocytogen will host a seminar at the BioJapan2022 Conference on Friday, October 14. The seminar, consisting of 3 modules, will introduce: Five RenMiceTM-based fully human…
Read more
Breakfast & Biotech with Biocytogen
Biocytogen eagerly invites fellow industrial partners and colleagues to join us for a Biotech and Breakfast session at the MassBio Hub. About this event Therapeutic…
Read more
Biocytogen Announces Collaboration with FineImmune to Develop TCR-Mimic Antibody-based Cell Therapy
Beijing and Guangzhou, China, September 15, 2022 -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced a strategic collaboration with Guangzhou FineImmune Biotechnology Co.,…
Read more
Webinar: Preclinical Pharmacokinetics (PK) and Pharmacodynamics (PD) Evaluation with Biocytogen
Our webinar “Preclinical Pharmacokinetics (PK) and Pharmacodynamics (PD) Evaluation with Biocytogen" was live on Sep 29, 2022 at 1PM EDT. An understanding of the exposure-response…
Read more
Research Impact: Custom Biocytogen mouse models used to identify critical mediator of inflammation-driven metastases
By John Charpentier, Ph.D. September 7, 2022 While metastases are ultimately responsible for the large majority of cancer deaths, most oncology drugs in development target…
Read more
Biocytogen Lists on the Main Board of HKEX, Aiming to Become the Headstream of New Drugs
Beijing, China, September 1, 2022 -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced the company’s official listing on the Main Board of the…
Read more
US FDA Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab
Beijing, China and San Diego, CA, August 29, 2022 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") and TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), today jointly announced…
Read more